USA flag logo/image

An Official Website of the United States Government

Rationally-designed, D-conformation Antimicrobial Peptides as Novel…

Award Information

Department of Defense
Award ID:
Program Year/Program:
2009 / STTR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
BioAMPS International LLC
12635 Montview Blvd. Suite 100 Aurora, CO 80045-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 1
Fiscal Year: 2009
Title: Rationally-designed, D-conformation Antimicrobial Peptides as Novel Antibacterial Drug Candidates for the Treatment of Multi-drug-resistant Bacterial
Agency / Branch: DOD / NAVY
Contract: N00014-09-M-0358
Award Amount: $69,960.00


Antimicrobial resistance is among the most challenging problems in microbiology and clinical medicine, and the DOD has seen a dramatic increase of resistant strains of MRSA and multi-drug-resistant Acinetobacter baumanii (MDR-AB) emerging in combat- and non-combat-related healthcare settings. Virulent/MDR infections are developing single/ multiple routes of resistance to the thirteen classes of currently available antiobiotics. New drugs now in trials hold little promise for major advances. Our BioAMPS/U. of Colorado STTR team proposes to pursue the much needed next-generation solution. We have developed a portfolio of alpha-helical antimicrobial peptides that exhibit broad-spectrum in vitro activity, and in Phase I we intend to prove the feasibility of identifying one or more lead peptide compounds that will function as effective antibacterials against MDR infections. Our novel, proprietary peptides target only the cytoplasmic membrane and do not require an interaction with a stereoselective receptor or pathway-an advantage that holds great potential for eliminating development of resistance. In Phase I we will screen three structurally unique series (13 analogs) of our peptides against 15 strains/isolates of MRSA and MDR-AB obtained from throughout the world to identify one or more novel antibacterial drug candidates for follow-on development in a larger Phase II STTR project.

Principal Investigator:

Robert Hodges
Principal Investigator

Business Contact:

David DeLong
Managing Member
Small Business Information at Submission:

BioAMPS International LLC
2256 Ash Street Denver, CO 80207

EIN/Tax ID: 262610248
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
University of Colorado Denver
MS F428, Anschutz Medical
13001 E. 17th Place, Room W112
Aurora, CO 80045
Contact: Lora Milhelic
Contact Phone: (303) 727-0090
RI Type: Nonprofit college or university